DaVita Inc. (NYSE:DVA) Receives Average Rating of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $161.80.

A number of brokerages recently issued reports on DVA. Truist Financial upped their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays boosted their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st.

DaVita Trading Up 3.1 %

DVA opened at $161.92 on Wednesday. The firm has a market capitalization of $13.28 billion, a price-to-earnings ratio of 17.47, a price-to-earnings-growth ratio of 0.86 and a beta of 0.92. The company’s 50 day simple moving average is $155.89 and its two-hundred day simple moving average is $152.20. DaVita has a 1-year low of $103.40 and a 1-year high of $169.51. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.85 EPS. Analysts expect that DaVita will post 9.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DVA. Transcendent Capital Group LLC purchased a new position in DaVita in the third quarter valued at $25,000. Blue Trust Inc. boosted its position in shares of DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after acquiring an additional 119 shares in the last quarter. Quarry LP acquired a new position in shares of DaVita during the 3rd quarter worth about $60,000. Point72 Hong Kong Ltd purchased a new position in shares of DaVita in the 2nd quarter valued at about $68,000. Finally, Versant Capital Management Inc raised its position in shares of DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.